scholarly journals Differences in Upper Quarter Y Balance Test Performance According to Playing Position in Youth Handball Players

2020 ◽  
Author(s):  
Julian Bauer ◽  
Gerrit Schwiertz ◽  
Thomas Muehlbauer
Keyword(s):  
Test Performance ◽  
Functional Performance ◽  
Effect Sizes ◽  
Second Line ◽  
First Line ◽  
Balance Test ◽  
Performance Differences ◽  
Distinctive Role

Abstract Objective Handball is an Olympic intermittent sport with different playing positions that can be differentiated between first line players who positions themselves near the 6-m line and second line players who typically play outside the 9-m space. Additionally, goalkeepers have a distinctive role as they mostly only play within their own 6-m space. The objective of the study was to assess whether the specific physiological positional demands in handball lead to functional performance differences between the playing positions in terms of shoulder mobility and stability in any reach direction as assessed through the Upper Quarter Y Balance Test (YBT-UQ). Results No significant differences in any reach direction of the YBT-UQ were found between the playing positions, irrespective of reach arm and reach direction. The obtained effect sizes (ηp2) were solely small and ranged between .003 and .030.

scholarly journals Diverging Playing Positions do not Lead to Differences in YBT-UQ Performance in Youth Handball Players

2021 ◽  
Vol 05 (03) ◽  
pp. E99-E103
Author(s):  
Julian Bauer ◽  
Gerrit Schwiertz ◽  
Thomas Muehlbauer
Keyword(s):  
Functional Performance ◽  
Cross Sectional Study ◽  
Training Load ◽  
Effect Sizes ◽  
Second Line ◽  
Sectional Study ◽  
First Line ◽  
Balance Test ◽  
Cross Sectional ◽  
Performance Differences

AbstractHandball playing positions can be differentiated between first line players who position themselves near the 6-m line and second line players who typically play outside the 9-m space. Handball is characterized by a high number of throwing actions that cause adaptations in the throwing shoulder. The objective of this cross-sectional study was to assess whether the specific physiological positional demands in handball lead to functional performance differences between the playing positions (N=196; goalkeepers: n=25; backcourt: n=99; pivots: n=21; winger: n=51) in terms of shoulder mobility and stability in any reach direction as assessed through the Upper Quarter Y Balance Test (YBT-UQ). Contrary to our hypothesis, the results did not show significant differences between the playing positions in shoulder mobility and stability in youth handball players, irrespective of reach arm and reach direction. The obtained effect sizes (η p 2) were solely small and ranged between 0.01 and 0.03. The adaptations following the demands of the diverging playing positions do not lead to significant differences in shoulder mobility and stability on the basis of the YBT-UQ. The overall training load of youth handball players may not be sufficient to lead to significant position-specific differences in shoulder mobility and stability.

Social Representations and Commitment

2018 ◽  
Vol 23 (3) ◽  
pp. 233-249 ◽  
Author(s):  
Eric Bonetto ◽  
Fabien Girandola ◽  
Grégory Lo Monaco
Keyword(s):  
Social Representations ◽  
Social Representation ◽  
Second Line ◽  
Review Of The Literature ◽  
First Line ◽  
Research Perspectives ◽  
The Social ◽  
Bibliographic Search ◽  
English Articles

Abstract. This contribution consists of a critical review of the literature about the articulation of two traditionally separated theoretical fields: social representations and commitment. Besides consulting various works and communications, a bibliographic search was carried out (between February and December, 2016) on various databases using the keywords “commitment” and “social representation,” in the singular and in the plural, in French and in English. Articles published in English or in French, that explicitly made reference to both terms, were included. The relations between commitment and social representations are approached according to two approaches or complementary lines. The first line follows the role of commitment in the representational dynamics: how can commitment transform the representations? This articulation gathers most of the work on the topic. The second line envisages the social representations as determinants of commitment procedures: how can these representations influence the effects of commitment procedures? This literature review will identify unexploited tracks, as well as research perspectives for both areas of research.

mCRPC: Cabazitaxel zukünftige Second-line-Option nach Docetaxel?

2010 ◽  
Vol 01 (06) ◽  
pp. 282-282
Author(s):  
Birgit-Kristin Pohlmann
Keyword(s):  
Second Line ◽  
First Line

Bislang steht für Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC), die auf die Standard-First-line-Chemotherapie mit Docetaxel nicht mehr adäquat ansprechen, keine Evidenz-basierte Therapieoption zur Verfügung. Große Hoffnungen verbinden sich daher mit Cabazitaxel, einer neuen Substanz, die diesen Patienten noch einmal die Chance auf eine Überlebenszeitverlängerung bietet. In den USA ist Cabazitaxel bereits für die Second-line-Behandlung beim mCRPC nach Docetaxel-Versagen zugelassen. In Europa ist die Zulassung für diese Indikation bean-tragt.

A Rational Sequencing of Anti-Angiogenic Agents as Second-Line Treatment Choice for mCRC Patients Progressing After a Bevacizumab-Based First Line

2020 ◽  
pp. 14-19
Author(s):  
Sara De Dosso
Keyword(s):  
Acquired Resistance ◽  
Predictive Biomarker ◽  
Cancer Therapies ◽  
Vascular Endothelial ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Vegf Pathway ◽  
Effective Choice ◽  
Endothelial Growth Factor

A large proportion of patients with metastatic colorectal cancer (mCRC) experience disease progression after first-line treatment with chemotherapy and bevacizumab, an anti-angiogenic agent, as a result of acquired resistance. However, blocking angiogenesis by targeted therapy towards the vascular endothelial growth factor (VEGF) pathway still forms an essential part of the second-line treatment strategy. Although three approved evidence-based choices for angiogenic agents (continuing treatment with bevacizumab, ramucirumab and aflibercept) are currently available in the second line, making the most effective choice is challenging due to the lack of studies directly comparing these agents. Moreover, despite huge investigational efforts, no predictive biomarker for anti-angiogenic cancer therapies could be identified so far.

Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer

2019 ◽  
Vol 21 (10) ◽  
pp. 718-724 ◽  
Author(s):  
Wen-Cong Ruan ◽  
Yue-Ping Che ◽  
Li Ding ◽  
Hai-Feng Li
Keyword(s):  
Colorectal Cancer ◽  
Adverse Event ◽  
Metastatic Colorectal Cancer ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Second Line Therapy ◽  
Clinical Prognosis ◽  
Line Therapy ◽  
Significant Difference

Background: Pre-treated patients with first-line treatment can be offered a second treatment with the aim of improving their poor clinical prognosis. The therapy of metastatic colorectal cancer (CRC) patients who did not respond to first-line therapy has limited treatment options. Recently, many studies have paid much attention to the efficacy of bevacizumab as an adjuvant treatment for metastatic colorectal cancer. Objectives: We aimed to evaluate the efficacy and toxicity of bevacizumab plus chemotherapy compared with bevacizumab-naive based chemotherapy as second-line treatment in people with metastatic CRC. Methods: Electronic databases were searched for eligible studies updated to March 2018. Randomized-controlled trials comparing addition of bevacizumab to chemotherapy without bevacizumab in MCRC patients were included, of which, the main interesting results were the efficacy and safety profiles of the addition of bevacizumab in patients with MCRC as second-line therapy. Result: Five trials were eligible in the meta-analysis. Patients who received the combined bevacizumab and chemotherapy treatment in MCRC as second-line therapy showed a longer overall survival (OS) (OR=0.80,95%CI=0.72-0.89, P<0.0001) and progression-free survival (PFS) (OR=0.69,95%CI=0.61-0.77, P<0.00001). In addition, there was no significant difference in objective response rate (ORR) (RR=1.36,95%CI=0.82-2.24, P=0.23) or severe adverse event (SAE) (RR=1.02,95%CI=0.88-1.19, P=0.78) between bevacizumab-based chemotherapy and bevacizumabnaive based chemotherapy. Conclusion: Our results suggest that the addition of bevacizumab to the chemotherapy therapy could be an efficient and safe treatment option for patients with metastatic colorectal cancer as second-line therapy and without increasing the risk of an adverse event.

scholarly journals Immediate hypersensitivity reaction followed by successful oral desensitization to ursodiol

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Erika Yue Lee ◽  
Christine Song
Keyword(s):  
Hypersensitivity Reaction ◽  
Primary Biliary Cholangitis ◽  
Line Treatment ◽  
Second Line ◽  
Immediate Hypersensitivity ◽  
First Line ◽  
Case Presentation ◽  
Desensitization Protocol ◽  
First Line Treatment ◽  
Oral Desensitization

Abstract Background Immediate hypersensitivity reaction to ursodiol is rare and there is no previously published protocol on ursodiol desensitization. Case presentation A 59-year-old woman with primary biliary cholangitis (PBC) developed an immediate hypersensitivity reaction to ursodiol—the first-line treatment for PBC. When she switched to a second-line treatment, her PBC continued to progress. As such, she completed a novel 12-step desensitization protocol to oral ursodiol. She experienced recurrent pruritus after each dose following desensitization, which subsided after a month of being on daily ursodiol. Conclusion Immediate hypersensitivity reaction to ursodiol is uncommon. Our case demonstrated that this novel desensitization protocol to ursodiol could be safely implemented when alternative options are not available or have proven inferior in efficacy.

scholarly journals Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

2021 ◽  
Author(s):  
B. González Astorga ◽  
F. Salvà Ballabrera ◽  
E. Aranda Aguilar ◽  
E. Élez Fernández ◽  
P. García-Alfonso ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Option ◽  
Scientific Evidence ◽  
Treatment Options ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Effective Therapeutic Option ◽  
Line Setting ◽  
First Line Treatment

AbstractColorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the first-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patient’s profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment.

Sign in / Sign up

Export Citation Format

Share Document